{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:52:53Z","timestamp":1792759973368,"version":"4.5.0"},"reference-count":84,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gene therapy using recombinant adeno-associated virus (rAAV) vectors has emerged as a transformative therapeutic modality for genetic disorders, demonstrating high transduction efficiency and a generally favorable safety profile during pre-clinical development. However, serious adverse events, including thrombotic microangiopathy, acute respiratory distress syndrome, hepatotoxicity, myocarditis, cytokine storm, and hemophagocytic lymphohistiocytosis, have been observed across multiple gene therapy clinical trials. Significant efforts have been made to understand the toxicities that cause these adverse events and clinical care for patients receiving gene therapies has evolved to mitigate their effects. These toxicities arise from a complex interplay between the innate and adaptive immune responses directed against the viral capsid and transgene products and are often compounded by pre-existing anti-AAV immunity. Immunomodulatory strategies have been developed to combat these responses to improve the long-term success of gene therapies, and this review provides clinicians managing gene therapy patients with an overview of mechanisms underlying AAV-associated immunotoxicities and a discussion of syndromes and mitigation strategies that have been reported in the clinical care of patients.<\/jats:p>","DOI":"10.3390\/ijms27073196","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:34:08Z","timestamp":1774974848000},"page":"3196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune Toxicities in AAV Gene Therapy: Overview for Clinicians"],"prefix":"10.3390","volume":"27","author":[{"given":"Shestruma","family":"Parajuli","sequence":"first","affiliation":[{"name":"Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-6902","authenticated-orcid":false,"given":"Thomas","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Department of Genetic and Cellular Medicine, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8255-0588","authenticated-orcid":false,"given":"Terence R.","family":"Flotte","sequence":"additional","affiliation":[{"name":"Department of Genetic and Cellular Medicine, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal Immunotoxicity in High-Dose Systemic AAV Therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-Associated Virus as a Delivery Vector for Gene Therapy of Human Diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune Response Mechanisms against AAV Vectors in Animal Models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-Existing Anti\u2013Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy","volume":"24","author":"Joergensen","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and Neutralizing Anti-AAV Antibodies: Detection and Implications for rAAV-Mediated Gene Therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101273","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global Seroprevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes Used for Human Gene Therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, X., Klann, P.J., Wiedtke, E., Sano, Y., Fischer, N., Schiller, L., Elfert, A., G\u00fcttsches, A.-K., Weyen, U., and Grimm, D. (2024). Seroprevalence of Binding and Neutralizing Antibodies against 18 Adeno-Associated Virus Types in Patients with Neuromuscular Disorders. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1450858"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41434-022-00353-2","article-title":"Clinical Enrollment Assay to Detect Preexisting Neutralizing Antibodies to AAV6 with Demonstrated Transgene Expression in Gene Therapy Trials","volume":"30","author":"Cao","year":"2023","journal-title":"Gene Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2023.018","article-title":"Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes","volume":"34","author":"West","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful Transduction of Liver in Hemophilia by AAV-Factor IX and Limitations Imposed by the Host Immune Response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Smith, C.J., Ross, N., Kamal, A., Kim, K.Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W.J., Singh, I., and Majowicz, A. (2022). Pre-Existing Humoral Immunity and Complement Pathway Contribute to Immunogenicity of Adeno-Associated Virus (AAV) Vector in Human Blood. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.999021"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chan, C., Harris, K.K., Zolotukhin, S., and Keeler, G.D. (2023). Rational Design of AAV-Rh74, AAV3B, and AAV8 with Limited Liver Targeting. Viruses, 15.","DOI":"10.3390\/v15112168"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101402","DOI":"10.1016\/j.omtm.2024.101402","article-title":"Reducing Off-Target Expression of mRNA Therapeutics and Vaccines in the Liver with microRNA Binding Sites","volume":"33","author":"Parrett","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and Safety of Voretigene Neparvovec (AAV2-hRPE65v2) in Patients with RPE65-Mediated Inherited Retinal Dystrophy: A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Kuranda","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterization of the Ocular Inflammatory Response to AAV Reveals Divergence by Sex and Age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-Based in Vivo Gene Therapy for Neurological Disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS Gene Delivery and Evasion of Anti-AAV-Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Manini, A., Abati, E., Nuredini, A., Corti, S., and Comi, G.P. (2022). Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.814174"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of Transgene Expression after rAAV Gene Therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ertl, H.C.J. (2021). T Cell-Mediated Immune Responses to AAV and AAV Vectors. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.666666"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2018.09.003","article-title":"Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.omtm.2020.05.001","article-title":"Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates","volume":"17","author":"Finn","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hum.2023.056","article-title":"Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies","volume":"34","author":"Kumar","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.125.2.509","article-title":"Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis","volume":"125","author":"Moss","year":"2004","journal-title":"Chest"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1089\/hum.2006.17.1177","article-title":"Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 \u03b1 1-Antitrypsin (AAT) Vector in AAT-Deficient Adults","volume":"17","author":"Brantly","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained Transgene Expression despite T Lymphocyte Responses in a Clinical Trial of rAAV1-AAT Gene Therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.ymthe.2025.05.017","article-title":"Lung Endothelial Transduction in a Patient That Succumbed to Acute Respiratory Distress Syndrome Following High-Dose rAAV9 Gene Therapy","volume":"33","author":"Hordeaux","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-Cell Responses to Adeno-Associated Virus Capsid in Humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of Immune Tolerance to Coagulation Factor IX Antigen by in Vivo Hepatic Gene Transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.ymthe.2022.11.007","article-title":"Secondary Hemophagocytic Lymphohistiocytosis Following Zolgensma Therapy: An Evolving Story on the Innate Response to Systemic Gene Therapy","volume":"30","author":"Byrne","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"Belluscio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate Immune Sensing of Adeno-Associated Virus Vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.jtha.2025.03.035","article-title":"Hemophilia Gene Therapy Enters Clinical Practice Aided by Clinical Guidance on Management of Transaminase Rise","volume":"23","author":"Coppens","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1111\/liv.16065","article-title":"Drug-induced Liver Injury Related to Gene Therapy: A New Challenge to Be Managed","volume":"44","author":"Larrey","year":"2024","journal-title":"Liver Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"131617","DOI":"10.1016\/j.ijcard.2023.131617","article-title":"Gene Therapy Vector-Related Myocarditis","volume":"398","author":"Silver","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hordeaux, J., Ramezani, A., Tuske, S., Mehta, N., Song, C., Lynch, A., Lupino, K., Chichester, J.A., Buza, E.L., and Dyer, C. (2023). Immune Transgene-Dependent Myocarditis in Macaques after Systemic Administration of Adeno-Associated Virus Expressing Human Acid Alpha-Glucosidase. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1094279"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/sj.gt.3303047","article-title":"AAV Vectors and Cardiovascular Disease: Targeting TNF Receptor in the Heart: Clue to Way Forward with AAV?","volume":"14","author":"Hajjar","year":"2007","journal-title":"Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.gt.3303020","article-title":"Myocarditis Following Adeno-Associated Viral Gene Expression of Human Soluble TNF Receptor (TNFRII-Fc) in Baboon Hearts","volume":"14","author":"McTiernan","year":"2007","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.ekir.2024.04.024","article-title":"Thrombotic Microangiopathy as an Emerging Complication of Viral Vector\u2013Based Gene Therapy","volume":"9","author":"Schwotzer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1212\/WNL.94.15_supplement.5483","article-title":"Thrombotic Microangiopathy (TMA): A Potential Adverse Reaction Post Zolgensma (Onasemnogene Abeparvovec-Xioi) Therapy for Spinal Muscular Atrophy (SMA) (5483)","volume":"94","author":"Prabhu","year":"2020","journal-title":"Neurology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-Induced Thrombocytopenia: The Role of von Willebrand Factor and P-Selectin in Mediating Accelerated Platelet Clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec\u2013A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e173510","DOI":"10.1172\/JCI173510","article-title":"Thrombotic Microangiopathy Following Systemic AAV Administration Is Dependent on Anti-Capsid Antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/bcp.70104","article-title":"The Clinical Toxicity of Advanced Therapy Medicinal Products","volume":"91","author":"Henderson","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/hum.2024.156","article-title":"Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases","volume":"36","author":"Laforet","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/01926233241298892","article-title":"Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors","volume":"52","author":"Assaf","year":"2024","journal-title":"Toxicol. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic Lymphohistiocytosis Following Gene Replacement Therapy in a Child with Type 1 Spinal Muscular Atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"Clin. Pharm. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene Therapy Community Grapples with Toxicity Issues, as Pipeline Matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The Clinical Landscape for AAV Gene Therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"155890","DOI":"10.1016\/j.cyto.2022.155890","article-title":"The IL-1 Cytokine Family as Custodians of Barrier Immunity","volume":"154","author":"Matarazzo","year":"2022","journal-title":"Cytokine"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Fields, J.K., G\u00fcnther, S., and Sundberg, E.J. (2019). Structural Basis of IL-1 Family Cytokine Signaling. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01412"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, N., Kumar, S.R.P., Cao, D., Munoz-Melero, M., Arisa, S., Brian, B.A., Greenwood, C.M., Yamada, K., Duan, D., and Herzog, R.W. (2024). Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer. Viruses, 16.","DOI":"10.3390\/v16101507"},{"key":"ref_64","unstructured":"Neurogene Inc. (2026, February 17). (via Public)\/ASGCT HLH+Presentation FINAL. Available online: https:\/\/Ebs.Publicnow.Com\/View\/3BADB3CACD69CF229751EC3CC14B7A6DFEC1D7F8."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-Dose Systemic Adeno-Associated Virus Vector Administration Causes Liver and Sinusoidal Endothelial Cell Injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2003.11.008","article-title":"CpG Methylation of a Plasmid Vector Results in Extended Transgene Product Expression by Circumventing Induction of Immune Responses","volume":"9","author":"Ertl","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2009.150","article-title":"Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy","volume":"17","author":"Arruda","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-Cleaving Endopeptidase Enables in Vivo Gene Therapy in the Presence of Anti-AAV Neutralizing Antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.xcrm.2025.102475","article-title":"Complete Neutralizing Antibody Evasion by Serodivergent Non-Mammalian AAVs Enables Gene Therapy Redosing","volume":"6","author":"Loeb","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"14033","DOI":"10.1038\/mtm.2014.33","article-title":"B-Cell Depletion Is Protective against Anti-AAV Capsid Immune Response: A Human Subject Case Study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0000000000002924","article-title":"IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-Strength Donor-Specific Antibody","volume":"268","author":"Lonze","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A Systematic Review of Immunosuppressive Protocols Used in AAV Gene Therapy for Monogenic Disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000546114","article-title":"Eculizumab for Thrombotic Microangiopathy Induced by Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"15","author":"Loboda","year":"2025","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_77","unstructured":"(2026, February 17). Treatment with Anakinra After Initially Receiving Tocilizumab for Cytokine Release Syndrome. Available online: https:\/\/www.Jhoponline.com\/Issue-Archive\/2024-Issues\/December-2024-Vol-14-No-6\/Treatment-with-Anakinra-after-Initially-Receiving-Tocilizumab-for-Cytokine-Release-Syndrome."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Zhou, Q., An, Y., Zhang, X., Xiao, X., Bai, X., Liu, P., Pu, Y., Meng, J., Zhu, H., and Lyu, C. (2025). Efficacy and Safety of Tocilizumab in Managing Cytokine Release Syndrome after CD19 CAR-T Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1530623"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of Action of Tacrolimus (FK506): Molecular and Cellular Mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2024-199915","article-title":"Prophylactic Administration of Glucocorticoids and Tacrolimus in AAV8-F8 Gene Therapy of Severe Haemophilia-a Achieved a Significant Long-Term Efficacy","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.omtm.2020.05.012","article-title":"rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates","volume":"18","author":"Ishii","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e177078","DOI":"10.1172\/JCI177078","article-title":"Improving the Safety of Systemic Viral Gene Therapy","volume":"134","author":"McNally","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101463","DOI":"10.1016\/j.omtm.2025.101463","article-title":"Lipid Nanoparticles: Composition, Formulation, and Application","volume":"33","author":"Xu","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:18:12Z","timestamp":1775276292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":84,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073196"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073196","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}